Avalo Therapeutics to Participate in The Citizens Life Sciences Conference

Rhea-AI Summary

Avalo Therapeutics, a clinical stage biotech company specializing in immune dysregulation treatments, has announced its upcoming participation in the Citizens Life Sciences Conference.

The company's CEO, Dr. Garry Neil, is scheduled to present at the conference on Thursday, May 8, 2025, at 3:00 pm ET in New York. The presentation will be accessible through live webcasts and replays from the company's website.

Investors and interested parties can access the presentation through:

• The "News / Events" section of Avalo's investor relations website at ir.avalotx.com
• Archived webcast replays available for a minimum of 30 days

Positive

• CEO participation in a major life sciences conference indicates continued market visibility and investor outreach efforts

Negative

• None.

News Market Reaction – AVTX

-0.40%

1 alert

-0.40% News Effect

On the day this news was published, AVTX declined 0.40%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will present at the Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 3:00 pm ET.

Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. For more information about Avalo, please visit www.avalotx.com.

About AVTX-009 

AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology.

For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793

or

Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com 

FAQ

When is Avalo Therapeutics (AVTX) presenting at the Citizens Life Sciences Conference 2025?

Avalo Therapeutics (AVTX) will present at the Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 3:00 pm ET.

How can I watch Avalo Therapeutics' (AVTX) presentation at the Citizens Life Sciences Conference?

The presentation can be watched via live webcast on Avalo's website at https://ir.avalotx.com under the 'News / Events' section in the Investors area. A replay will be available for at least 30 days.

What is the focus area of Avalo Therapeutics (AVTX)?

Avalo Therapeutics (AVTX) is a clinical stage biotechnology company specifically focused on the treatment of immune dysregulation.

Who will represent Avalo Therapeutics (AVTX) at the Citizens Life Sciences Conference 2025?

Dr. Garry Neil, Chief Executive Officer of Avalo Therapeutics, will present at the conference.

How long will Avalo Therapeutics' (AVTX) conference presentation replay be available?

The archived webcast of the presentation will be available for replay for at least 30 days on Avalo's investor relations website.